Cyclo-oxygenase 2 inhibitor, nabumetone, inhibits proliferation in chronic myeloid leukemia cell lines.
Leuk Lymphoma
; 46(5): 753-6, 2005 May.
Article
en En
| MEDLINE
| ID: mdl-16019514
ABSTRACT
The anti-tumor effect of cyclo-oxygenase (COX) inhibitors has been documented in several studies. COX2 inhibitors have attracted more attention because of the fewer side-effects and the more prominent anti-tumor effects. However, experience with these drugs in hematological malignancies is limited. In our study, a potent COX2 inhibitor, nabumetone (NBT), was investigated for its anti-proliferative and apoptotic effects in K-562 and Meg-01 chronic myeloid leukemia blastic cell lines as a single agent or in combination with adriamycin (ADR) and interferon alpha (IFN-a). In these cell lines, a dose-dependent inhibition of proliferation was observed with NBT. We observed no significant apoptotic effect of NBT. However, NBT potentiated the apoptotic effect of ADR in the K-562 cell line. Bcl-2 expression was reduced by NBT (11% vs. 2%). The combination of NBT with IFN did not have any significant effect on the K-562 cell line. We suggest that NBT inhibits proliferation and potentiates the apoptotic effect of ADR in chronic myeloid leukemia cell lines.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Butanonas
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Inhibidores de la Ciclooxigenasa
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Año:
2005
Tipo del documento:
Article